Doctors stole her cells without telling her. Decades later, those same cells are helping fuel a new race to save patients with rare and deadly diseases. As U.S. regulators move to speed up cutting-edge gene therapies, the story of a young woman from Roanoke — and the cells taken from her body in 1951 — is once again at the center of modern medicine.

Roanoke, VA

Author: Roanoke Rambler Staff, Tina Antwi Lead

Published: 9:30 PM EST June 9, 2026

Edited: 9:30 PM EST June 9, 2026

More than 70 years after her death, a young woman from Roanoke continues to shape modern medicine. Cells taken from her body in 1951 are still driving breakthroughs, helping scientists around the world develop treatments for cancer, infectious diseases, and a new generation of gene therapies that could transform care for patients with rare and life-threatening illnesses.

The woman was Henrietta Lacks. She never knew her cells had been taken. Yet few people have had a greater impact on modern medicine.

This week, the U.S. Food and Drug Administration unveiled new draft guidance aimed at accelerating gene therapies for rare diseases, bringing the story of Henrietta Lacks into renewed focus. Advances in science pushing toward faster, more personalized treatments are built on decades of cellular research made possible in part by the HeLa cells that originated from a Roanoke native.

With an estimated 30 million people living with rare diseases, the agency’s latest proposal could help bring experimental treatments to patients faster — and it underscores how a scientific legacy that began with a woman born in Roanoke continues to shape medicine today. This is more than a regulatory update; it is another chapter in a scientific story that began more than seven decades ago.

The debate is no longer whether these therapies work — many already do. The question now is how quickly regulators can safely bring promising treatments to patients who have few or no alternatives.

Supporters argue the FDA’s proposal could shorten development timelines and encourage investment in treatments for conditions that pharmaceutical companies have historically overlooked. Critics caution that faster pathways must still be supported by strong evidence and careful monitoring after approval.

Both sides agree on one thing: medicine is entering a new era. And as that era unfolds, the legacy of a woman born in Roanoke continues to be part of the foundation beneath it.

In 1951, Lacks sought treatment at Johns Hopkins Hospital after experiencing unusual bleeding. During her care for an aggressive form of cervical cancer, doctors collected samples of both cancerous and healthy cervical tissue without her knowledge or consent — a common practice at the time. The samples were sent to cancer researcher Dr. George Gey. What happened next changed medicine forever.

Unlike most human cells, which survive only a matter of days in laboratory conditions, Henrietta’s cancer cells proved remarkably resilient. They doubled approximately every 20 to 24 hours and continued reproducing indefinitely. Scientists named them “HeLa” cells, using the first two letters of her first and last names. They became the first immortalized human cell line and remain one of the most important tools in medical research.

HeLa cells helped scientists develop the polio vaccine, advance cancer treatments, study viruses, improve in vitro fertilization techniques, and contribute to gene-mapping research. Today they are used in laboratories around the globe. Few scientific discoveries have touched as many areas of medicine.

Henrietta Lacks died on October 4, 1951, at the age of 31. Yet her contributions to science continue more than seven decades later. On June 2, 2026, the FDA issued draft guidance designed to accelerate the development of gene therapies by allowing researchers and companies to make greater use of existing scientific and regulatory knowledge. The proposal would enable developers to rely on previously established manufacturing data, clinical information, and scientific findings — reducing unnecessary duplication of research and potentially bringing treatments to patients more quickly.

“For patients living with serious or rare diseases, time matters,” said Dr. Vijay Kumar, Acting Director of the Office of Therapeutic Products within the FDA’s Center for Biologics Evaluation and Research. “Leveraging prior knowledge does not mean lowering the bar; it means raising our collective efficiency while maintaining the highest standards of safety and efficacy.”

The guidance is particularly significant for rare and life-threatening diseases, where patient populations are often too small to support traditional large-scale clinical trials. Under the FDA’s evolving framework, developers may have greater flexibility to demonstrate effectiveness and safety when conventional randomized studies are not feasible. According to the National Organization for Rare Disorders, more than 30 million Americans live with a rare disease, and fewer than five percent of those conditions have an approved treatment.

In many ways, this new generation of gene and cell therapies builds upon a foundation that Henrietta Lacks helped create. Before the discovery of HeLa cells, scientists often struggled to keep human cells alive long enough to conduct meaningful experiments. HeLa cells changed that reality, providing researchers with a stable and reproducible tool that accelerated decades of scientific progress.

Her story also continues to raise difficult questions about ethics, informed consent, and the relationship between patients and medical research. The scientific breakthroughs made possible by HeLa cells generated enormous medical and commercial value, while Lacks herself never knew her cells had been taken and her family received no compensation for many decades.

As medicine enters an era increasingly defined by gene editing, personalized therapies, and RNA-based treatments, those questions remain as relevant as ever.

The FDA’s latest effort to speed treatments for rare diseases is ultimately a story about time — time that patients battling devastating illnesses often do not have. That reality makes Henrietta Lacks’ story impossible to ignore.

Roanoke produced one of the most consequential figures in the history of modern medicine. This week, the FDA took another step in a scientific journey her cells helped make possible. Henrietta Lacks never knew what she had given the world. But the world is still building on it.

The Roanoke Rambler Staff